MX2020000144A - Composicion farmaceutica para administracion nasal. - Google Patents
Composicion farmaceutica para administracion nasal.Info
- Publication number
- MX2020000144A MX2020000144A MX2020000144A MX2020000144A MX2020000144A MX 2020000144 A MX2020000144 A MX 2020000144A MX 2020000144 A MX2020000144 A MX 2020000144A MX 2020000144 A MX2020000144 A MX 2020000144A MX 2020000144 A MX2020000144 A MX 2020000144A
- Authority
- MX
- Mexico
- Prior art keywords
- rifampicin
- pharmaceutical composition
- nasal administration
- liver
- brain
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 abstract 4
- 229960001225 rifampicin Drugs 0.000 abstract 4
- 210000004556 brain Anatomy 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 210000004185 liver Anatomy 0.000 abstract 2
- 230000007774 longterm Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
El propósito de la presente invención es proporcionar una técnica de dosificación para rifampicina, la técnica es capaz de administración a largo plazo al mejorar la transferencia directa de rifampicina al cerebro, y al suprimir el efecto de primer paso hepático; esta composición farmacéutica para administración nasal, que contiene, como un ingrediente activo, rifampicinas seleccionadas del grupo que consiste en rifampicina, derivados de la misma, y sales de la misma, y se utiliza para la prevención o tratamiento de demencia, es capaz de administración a largo plazo al mejorar la transferencia directa de rifampicina al cerebro y suprimir el efecto de primer paso hepático.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017132955 | 2017-07-06 | ||
| PCT/JP2018/025512 WO2019009359A1 (ja) | 2017-07-06 | 2018-07-05 | 経鼻投与用医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020000144A true MX2020000144A (es) | 2020-07-22 |
Family
ID=64951007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020000144A MX2020000144A (es) | 2017-07-06 | 2018-07-05 | Composicion farmaceutica para administracion nasal. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11583494B2 (es) |
| EP (1) | EP3650024B1 (es) |
| JP (1) | JP7146281B2 (es) |
| CN (1) | CN110831598A (es) |
| CA (1) | CA3068690A1 (es) |
| DK (1) | DK3650024T3 (es) |
| ES (1) | ES2970909T3 (es) |
| FI (1) | FI3650024T3 (es) |
| HU (1) | HUE065421T2 (es) |
| MX (1) | MX2020000144A (es) |
| PL (1) | PL3650024T3 (es) |
| PT (1) | PT3650024T (es) |
| WO (1) | WO2019009359A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102051624B1 (ko) * | 2018-11-30 | 2019-12-02 | 아밀로이드솔루션 주식회사 | 트리플루프로마진 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 퇴행성 뇌질환 치료용 약학 조성물 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7949794A (en) * | 1993-10-20 | 1995-05-08 | Teijin Limited | Amyloid beta -protein agglutination and/or deposition inhibitor |
-
2018
- 2018-07-05 HU HUE18828851A patent/HUE065421T2/hu unknown
- 2018-07-05 PT PT188288518T patent/PT3650024T/pt unknown
- 2018-07-05 MX MX2020000144A patent/MX2020000144A/es unknown
- 2018-07-05 PL PL18828851.8T patent/PL3650024T3/pl unknown
- 2018-07-05 CN CN201880044459.8A patent/CN110831598A/zh active Pending
- 2018-07-05 ES ES18828851T patent/ES2970909T3/es active Active
- 2018-07-05 FI FIEP18828851.8T patent/FI3650024T3/fi active
- 2018-07-05 DK DK18828851.8T patent/DK3650024T3/da active
- 2018-07-05 JP JP2019527959A patent/JP7146281B2/ja active Active
- 2018-07-05 CA CA3068690A patent/CA3068690A1/en active Pending
- 2018-07-05 US US16/628,476 patent/US11583494B2/en active Active
- 2018-07-05 EP EP18828851.8A patent/EP3650024B1/en active Active
- 2018-07-05 WO PCT/JP2018/025512 patent/WO2019009359A1/ja active Search and Examination
Also Published As
| Publication number | Publication date |
|---|---|
| CA3068690A1 (en) | 2019-01-10 |
| DK3650024T3 (da) | 2023-12-04 |
| ES2970909T3 (es) | 2024-05-31 |
| FI3650024T3 (fi) | 2023-12-12 |
| WO2019009359A1 (ja) | 2019-01-10 |
| HUE065421T2 (hu) | 2024-05-28 |
| JPWO2019009359A1 (ja) | 2020-07-27 |
| PL3650024T3 (pl) | 2024-03-18 |
| EP3650024B1 (en) | 2023-10-25 |
| PT3650024T (pt) | 2023-12-14 |
| US11583494B2 (en) | 2023-02-21 |
| EP3650024A1 (en) | 2020-05-13 |
| US20200129426A1 (en) | 2020-04-30 |
| JP7146281B2 (ja) | 2022-10-04 |
| CN110831598A (zh) | 2020-02-21 |
| EP3650024A4 (en) | 2021-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500591A1 (en) | Heterocyclic compounds and uses thereof | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| PH12019502201A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12019502577A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12018502026A1 (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| BR112017003054A2 (pt) | compostos de aminopirimidinila como inibidores de jak | |
| PH12018502077A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12019502095A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| MX2018011788A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| PH12019502559A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12018502015A1 (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| MX2016016516A (es) | Inhibidores de fosfatidilinositol 3-cinasa. | |
| EA202090688A1 (ru) | Бис-амидные соединения, активирующие саркомер, и варианты их применения | |
| MY197698A (en) | Oxysterols and methods of use thereof | |
| TN2017000075A1 (en) | Compounds and compositions as raf kinase inhibitors | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| MX2016016530A (es) | Inhibidores de fosfatidilinositol 3-quinasa. | |
| NZ725399A (en) | Macrocylic pyrimidine derivatives | |
| HK1257615A1 (zh) | 用於治療癌症、含有多酚化合物作為活性成分的藥物組合物 | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| MX2018016339A (es) | Compuestos heterociclicos antiinfecciosos y sus usos. | |
| PH12016501733A1 (en) | Pharmaceutical composition for preventing or treating skin rash | |
| MX2017013101A (es) | Piridopirimidinonas y utilizacion de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda). | |
| MX2020000144A (es) | Composicion farmaceutica para administracion nasal. | |
| PH12020550549A1 (en) | Compositions for preventing or treating lupus |